Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q969G3
UPID:
SMCE1_HUMAN
Alternative names:
BRG1-associated factor 57
Alternative UPACC:
Q969G3; B3KMC1; B4DFR4; C0IMW4; C0IMW5; C0IMW7; H7C3F6; O43539
Background:
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1, also known as BRG1-associated factor 57, plays a pivotal role in chromatin remodeling. It is involved in transcriptional activation and repression by altering DNA-nucleosome topology in an ATP-dependent manner. This protein is a component of both the npBAF and nBAF complexes, crucial for neural development and differentiation.
Therapeutic significance:
The protein's involvement in diseases like Meningioma and Coffin-Siris syndrome 5 highlights its potential as a target for therapeutic intervention. Understanding the role of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 could open doors to potential therapeutic strategies.